The FDA approved a fast review of¬† a new Melanoma drug used in a clinical trial at 125 U.S. cancer centers. The study, published in the New England Journal of Medicine on Aug. 19, shows about 23 percent of the patients given ipilimumab¬†are alive two years later, compared with 14 percent of those who did not receive the drug. Those taking ipilimumab lived a median of about 10 months, compared with 6.4 months for those …